ClinicalTrials.gg
CompletedNCT07935499HealingUpdated Nov 13, 2026

Muscle Relaxation Technique on Neuropathic Pain

An interventional study of Progressive Muscle Relaxation (PMR) in Diabetes Mellitus and Diabetes Mellitus Type 2, sponsored by Al-Zaytoonah University of Jordan. Completed at 1 site in Jordan. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Al-Zaytoonah University of Jordan · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Sep 2025, registered Nov 2026).
Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 24 studies in Diabetes Mellitus, Type 2 with a site in Jordan — 2 open to participants now, 3 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Jordan.

Enrollment
13th of 18
96 · median 178
Started
2025
with 1 other
No phase
11 of 24
1 open now
Registered
24th of 24
by date
Lead sponsor
1 of 24
Al-Zaytoonah University of Jordan

Among the 24 studies in Diabetes Mellitus, Type 2 with a site in Jordan, this one is the 13th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 with no phase, and was the 24th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 24 studies in Diabetes Mellitus, Type 2 with a site in Jordan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Jordan have not opened yet or have stopped. Only those recruiting at a site in Jordan →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Diabetes Mellitus, Type 2 with a site in Jordan, or all of them as a file.
02

Study summary

This study aims to evaluate the effect of progressive muscle relaxation (PMR) on neuropathic pain and fatigue among elderly patients with diabetes mellitus.

Diabetic neuropathy can cause pain, discomfort, and fatigue, which may negatively affect the daily activities and quality of life of older adults. Progressive muscle relaxation is a non-pharmacological technique that involves systematically tensing and relaxing different muscle groups to promote physical relaxation and reduce discomfort.

The study includes 96 elderly patients with diabetes mellitus who are divided into two groups. The intervention group receives progressive muscle relaxation in addition to routine care, while the control group receives routine care alone.

Neuropathic pain is assessed using the Douleur Neuropathique 4 (DN4) questionnaire and the Numeric Pain Rating Scale (NPRS). Fatigue is assessed using the Fatigue Severity Scale (FSS).

The study evaluates whether progressive muscle relaxation can reduce neuropathic pain and fatigue severity among elderly patients with diabetes mellitus.

Read the detailed description

Diabetes mellitus is a chronic metabolic condition associated with several complications, including diabetic peripheral neuropathy. Neuropathic pain is a common and distressing complication that may interfere with sleep, mobility, daily activities, and overall well-being. Fatigue is another frequently reported symptom among older adults with diabetes and may further affect their functional independence and quality of life.

Progressive muscle relaxation (PMR) is a non-pharmacological relaxation technique involving the systematic tensing and subsequent relaxing of different muscle groups. It is intended to promote physical relaxation, reduce muscular tension, and support the management of pain and fatigue.

This quasi-experimental study uses a study-control group design to evaluate the effect of progressive muscle relaxation on neuropathic pain and fatigue among elderly patients with diabetes mellitus.

The study will be conducted at the diabetes clinic of Abu Bakr Al-Siddiq Clinics Complex, affiliated with the General Authority for Health Insurance, in Shebin El-Kom, Menoufia Governorate, Egypt.

A purposive sample of 96 elderly patients with diabetes mellitus will participate. Participants are allocated into two equal groups:

  • **Study group:** 48 participants receiving progressive muscle relaxation in addition to routine care.
  • **Control group:** 48 participants receiving routine care.

Data collection instruments include:

  1. **Structured Interviewing Questionnaire:** Collects sociodemographic and clinical characteristics of participants.
  2. **Douleur Neuropathique 4 (DN4) Questionnaire:** Assesses the presence and characteristics of neuropathic pain.
  3. **Numeric Pain Rating Scale (NPRS):** Measures the severity of pain.
  4. **Fatigue Severity Scale (FSS):** Assesses the severity and impact of fatigue.

The primary focus is to evaluate changes in neuropathic pain and fatigue following the progressive muscle relaxation intervention. The study also examines the relationship between neuropathic pain and fatigue severity.

The findings may contribute to evidence regarding the use of simple, non-pharmacological nursing interventions to support symptom management among elderly patients living with diabetes mellitus.

03

Conditions studied

  • Diabetes Mellitus
  • Diabetes Mellitus Type 2

Browse trials for

Keywords

  • Progressive Muscle Relaxation Technique Diabetes Mellitus Elderly Patients
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

This study's enrollment of 96 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Al-Zaytoonah University of Jordan is the lead sponsor of 33 studies on the registry; 6 are open to participants now.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

**Inclusion Criteria:**

  1. Older adults aged 60 years or above.
  2. Individuals diagnosed with diabetes mellitus.
  3. Patients attending the diabetes clinic at Abu Bakr Al-Siddiq Clinics Complex, Shebin El-Kom, Menoufia Governorate, Egypt.
  4. Individuals willing to participate in the study and provide .
  5. Individuals able to understand and follow the progressive muscle relaxation instructions and complete the study assessment questionnaires.

**Exclusion Criteria:** Participants with conditions that prevent them from safely performing the progressive muscle relaxation exercises, if specified in the approved study protocol.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Progressive Muscle Relaxation Group

    Participants in this group (n=48) receive progressive muscle relaxation (PMR) training in addition to routine care. The intervention involves systematic tensing and relaxing of different muscle groups to promote relaxation and help reduce neuropathic pain and fatigue associated with diabetes mellitus. Participants receive the intervention according to the study protocol. Neuropathic pain and fatigue are assessed using the Douleur Neuropathique 4 (DN4) questionnaire, Numeric Pain Rating Scale (NPRS), and Fatigue Severity Scale (FSS).

    Behavioral: Progressive Muscle Relaxation (PMR)

  • No intervention
    Routine Care Control Group

    Participants in this group (n=48) receive routine care provided at the diabetes clinic without the progressive muscle relaxation intervention. Neuropathic pain and fatigue are assessed using the same study instruments as the intervention group: the Douleur Neuropathique 4 (DN4) questionnaire, Numeric Pain Rating Scale (NPRS), and Fatigue Severity Scale (FSS).

Interventions

  • BehavioralProgressive Muscle Relaxation (PMR)

    Progressive muscle relaxation (PMR) is a structured behavioral relaxation technique involving the systematic tensing and subsequent relaxing of different muscle groups. It is provided to elderly patients with diabetes mellitus as a non-pharmacological nursing intervention intended to promote relaxation and help manage neuropathic pain and fatigue. The intervention is delivered to participants in the experimental group in addition to routine diabetes care, according to the study protocol. The control group receives routine care without PMR.

07

What researchers measure

Primary outcomes

  1. Change in Neuropathic Pain Severity

    Neuropathic pain severity will be assessed using the Numeric Pain Rating Scale (NPRS), a scale ranging from 0 (no pain) to 10 (worst imaginable pain). Changes in pain scores will be evaluated by comparing measurements before and after the intervention between the progressive muscle relaxation group and the routine care group.

    Time frame: Baseline and immediately after completion of the intervention

08

Study locations

1 site
  • Menoufia University Hospitals
    Amman, 00000, Jordan
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Jan 2026, 4 months.

Of 2,070 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 4 months is below that.

Counting every sponsor, half of 2,247 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 13, 2026
StartActual
Sep 4, 2025
Primary completionActual
Jan 5, 2026
CompletionActual
Jan 7, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07935499
Lead sponsor
Al-Zaytoonah University of Jordan
Responsible party
Eman Abdelfatah Shokr (Dr, Al-Zaytoonah University of Jordan) — Principal investigator
First posted
Nov 13, 2026
Start date
Sep 4, 2025
Primary completion
Jan 5, 2026
Completion
Jan 7, 2026
Last update
Nov 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion